IVA Fundamental Analysis - INVENTIVA SA

Fundamental Rating

IVA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 83 industry peers in the Biotechnology industry. Both the profitability and financial health of IVA have multiple concerns. While showing a medium growth rate, IVA is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year IVA has reported negative net income.

IVA had a negative operating cash flow in the past year.

In the past 5 years IVA always reported negative net income.

IVA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

IVA has a worse Return On Assets (-173.74%) than 89.16% of its industry peers.

		Industry Rank	Sector Rank
ROA	-173.74%
ROE	N/A
ROIC	N/A

ROA(3y)-119.52%

ROA(5y)-84.69%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

IVA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

IVA does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for IVA has been increased compared to 1 year ago.

Compared to 5 years ago, IVA has more shares outstanding

The debt/assets ratio for IVA has been reduced compared to a year ago.

2.2 Solvency

IVA has an Altman-Z score of -1.70. This is a bad value and indicates that IVA is not financially healthy and even has some risk of bankruptcy.

IVA has a worse Altman-Z score (-1.70) than 61.45% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-1.7

ROIC/WACCN/A

WACC7.82%

2.3 Liquidity

A Current Ratio of 2.98 indicates that IVA has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 2.98, IVA is in the better half of the industry, outperforming 61.45% of the companies in the same industry.

IVA has a Quick Ratio of 2.98. This indicates that IVA is financially healthy and has no problem in meeting its short term obligations.

IVA's Quick ratio of 2.98 is fine compared to the rest of the industry. IVA outperforms 66.27% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.98
Quick Ratio	2.98

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for IVA have decreased strongly by -74.31% in the last year.

IVA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -12.84%.

IVA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.62% yearly.

EPS 1Y (TTM)-74.31%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-71.76%

Revenue 1Y (TTM)-12.84%

Revenue growth 3Y29.92%

Revenue growth 5Y5.62%

Sales Q2Q%10763.41%

3.2 Future

IVA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.26% yearly.

Based on estimates for the next years, IVA will show a very strong growth in Revenue. The Revenue will grow by 123.56% on average per year.

EPS Next Y43.78%

EPS Next 2Y24.76%

EPS Next 3Y14.52%

EPS Next 5Y16.26%

Revenue Next Year-15.08%

Revenue Next 2Y-39.27%

Revenue Next 3Y62.43%

Revenue Next 5Y123.56%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IVA. In the last year negative earnings were reported.

Also next year IVA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as IVA's earnings are expected to grow with 14.52% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y24.76%

EPS Next 3Y14.52%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

IVA does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

INVENTIVA SA

EPA:IVA (12/12/2025, 7:00:00 PM)

3.76

-0.04 (-1.05%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-21 2025-11-21

Earnings (Next)02-16 2026-02-16/amc

Inst Owners43.01%

Inst Owner ChangeN/A

Ins Owners4.97%

Ins Owner ChangeN/A

Market Cap718.23M

Revenue(TTM)13.61M

Net Income(TTM)-311.00M

Analysts87.14

Price Target12.18 (223.94%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)4.6%

PT rev (3m)13.09%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)7.95%

EPS NY rev (3m)-56.11%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-0.25%

Revenue NY rev (3m)-73.55%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	52.77
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-3.62

EYN/A

EPS(NY)-0.99

Fwd EYN/A

FCF(TTM)-0.48

FCFYN/A

OCF(TTM)-0.48

OCFYN/A

SpS0.07

BVpS-0.05

TBVpS-0.05

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-173.74%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-119.52%

ROA(5y)-84.69%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0.08

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	1.75%
Cap/Sales	0.96%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.98
Quick Ratio	2.98
Altman-Z	-1.7

F-Score4

WACC7.82%

ROIC/WACCN/A

Cap/Depr(3y)20.05%

Cap/Depr(5y)N/A

Cap/Sales(3y)3.76%

Cap/Sales(5y)20.5%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-74.31%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-71.76%

EPS Next Y43.78%

EPS Next 2Y24.76%

EPS Next 3Y14.52%

EPS Next 5Y16.26%

Revenue 1Y (TTM)-12.84%

Revenue growth 3Y29.92%

Revenue growth 5Y5.62%

Sales Q2Q%10763.41%

Revenue Next Year-15.08%

Revenue Next 2Y-39.27%

Revenue Next 3Y62.43%

Revenue Next 5Y123.56%

EBIT growth 1Y2.04%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year8.14%

EBIT Next 3Y3.93%

EBIT Next 5Y21.53%

FCF growth 1Y-42.99%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-43.88%

OCF growth 3YN/A

OCF growth 5YN/A

INVENTIVA SA / IVA.PA FAQ

What is the ChartMill fundamental rating of INVENTIVA SA (IVA.PA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to IVA.PA.

What is the valuation status of INVENTIVA SA (IVA.PA) stock?

ChartMill assigns a valuation rating of 0 / 10 to INVENTIVA SA (IVA.PA). This can be considered as Overvalued.

Can you provide the profitability details for INVENTIVA SA?

INVENTIVA SA (IVA.PA) has a profitability rating of 0 / 10.

How financially healthy is INVENTIVA SA?

The financial health rating of INVENTIVA SA (IVA.PA) is 0 / 10.

INVENTIVA SA (IVA.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

INVENTIVA SA / IVA.PA FAQ

What is the ChartMill fundamental rating of INVENTIVA SA (IVA.PA) stock?

What is the valuation status of INVENTIVA SA (IVA.PA) stock?

Can you provide the profitability details for INVENTIVA SA?

How financially healthy is INVENTIVA SA?